Beatrice Setnik

Dr. Setnik has been working in the area of clinical drug development and abuse potential (AP) assessment since 2005.  Dr. Setnik is currently the Chief Scientific Officer at Altasciences and an Adjunct Professor at the University of Toronto (Department of Pharmacology and Toxicology).  Dr. Setnik earned her doctorate degree in Pharmacology and the Collaborative Program in Neuroscience from the University of Toronto in 2005.  In her former role as Vice President of Scientific & Medical Affairs at INC Research/inVentiv Health (Early Phase), she was responsible for scientific input on early phase clinical trials and in strategic initiatives in business growth and development.  In her previous role as Senior Director, Clinical Sciences (King Pharmaceuticals and Pfizer, Inc), Dr. Setnik lead the clinical development, regulatory filing, and lifecycle management, including abuse potential evaluation, of several pain compounds including abuse deterrent opioid formulations. In her previous role as a Research Scientist (formerly Ventana / Decisionline Clinical Research, Toronto, Canada), Dr. Setnik was responsible for providing scientific input on various specialty phase I-II clinical trials including abuse potential studies for CNS drugs.   Dr. Setnik has published numerous research articles in internationally recognized peer-reviewed journals and has presented at over 200 scientific meetings and conferences.  In addition, she is the Managing Director and Clinical subgroup lead Cross Company Abuse Liability Council and chair of the Clinical Pharmacology Community of the Drug Information Association (DIA). Dr. Setnik is also an active member and participant in several congresses including the College on Problems of Drug Dependence. She has also been actively engaged in many aspects of abuse potential assessment including development of patient reported outcome instruments and contributing to post-marketing surveillance studies.